



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents,  
Washington, D.C. 20231 on May 16, 2000

Frank C Eisenschenk  
Frank C. Eisenschenk, Ph.D., Patent Attorney

AMENDMENT UNDER  
37 CFR 1.825(a) THROUGH (c)  
Examining Group 1644  
Patent Application  
Docket No. SPO-103  
Serial No. 09/142,524

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : M. DiBrino, Ph.D.  
Art Unit : 1644  
Applicant(s) : Toshio Sone, Akinori Kume, Kazuo Dairiki, Akiko Iwama, Kohsuke Kino  
Serial No. : 09/142,524  
Filed : September 9, 1998  
For : Peptide-based Immunotherapeutic Agent for Treating Allergic Diseases

Box SEQUENCE

Assistant Commissioner for Patents  
Washington, D.C. 20231

AMENDMENT UNDER 37 CFR 1.825(a) THROUGH (c)

Sir:

In response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures received in the above-identified patent application, please amend the subject application as follows:

In the Specification

Please replace pages 1-3 of the sequence listing with the accompanying sequence listing as new pages 1-5.